Are private joint injections worth it for you?

Paying privately for a joint or tendon injection often comes down to one practical trade-off: the upfront cost versus the chance of meaningful symptom relief in the next few weeks or months, especially when public pathways can involve long waits or limited access to certain injection options.

This guide is organised around five common situations seen in clinic in Lincolnshire:

• Arthrosamid (polyacrylamide hydrogel) for knee osteoarthritis
• Hyaluronic acid (HA) versus corticosteroid injections for hip osteoarthritis
• ChondroFiller (injectable collagen scaffold) for focal knee cartilage defects
• Lipogems / microfragmented adipose tissue (mFAT) for multi-compartment knee osteoarthritis
• Corticosteroid injections for greater trochanteric pain syndrome (GTPS) — often labelled “hip bursitis”, and frequently related to gluteal tendinopathy

Across these five, the decision usually hinges on the same points: likely duration of benefit (for example, weeks versus months versus longer), the main risks, how results compare with alternatives (including rehabilitation, no injection, or surgery), and whether the probability of benefit fits the specific problem being treated.

To keep the focus on real decisions rather than an “SEO template”, the sections that follow use a scenario-led structure and are explicit where evidence is strong, mixed, or limited. These treatments are commonly delivered as outpatient, image-guided injections (often ultrasound-guided) under local anaesthetic, without hospital admission or general anaesthesia; individual suitability depends on diagnosis, comorbidities, and assessment.

Is Arthrosamid knee injection worth the private cost?

Rather than treating “worth it?” as a yes/no question, Arthrosamid tends to make most sense when the aim is to pay once for the chance of longer-lasting knee osteoarthritis symptom relief than standard injections.

What Arthrosamid is (and what it is trying to do)

Arthrosamid is a 2.5% polyacrylamide hydrogel studied as a single 6 mL intra-articular injection for knee osteoarthritis.

What durability can look like

In a 5-year extension of a randomised trial in moderate–severe knee OA, a single iPAAG (Arthrosamid) injection was associated with sustained improvements across WOMAC pain, stiffness and function; the average WOMAC pain improvement at year 5 was about 16 points on a 0–100 scale, and no serious adverse events were attributed to the implant over that period. This is a durability signal that goes well beyond the usual months-long horizon expected from many standard injections, while still recognising that not everyone maintains multi-year benefit.

Who tends to get the best “value” from one injection

In a 314-knee 24‑month outcomes cohort, symptom scores improved overall, but clinically important improvements were more likely in patients who were older, non-diabetic, and had lower radiographic OA grade. The same cohort also reported progression to total knee replacement within 2 years in a subset, with higher OA grades more likely to proceed to surgery—so advanced knees may still move towards replacement even if symptoms ease for a period.

How it stacks up against steroid and HA over 12 months

A retrospective comparison of 150 people receiving iPAAG, HA, or corticosteroid injections found that all three groups improved at 3 months. At 6 months, iPAAG outcomes were better than corticosteroid and similar to HA; by 12 months, steroid and HA results had largely drifted back towards baseline, while iPAAG remained somewhat improved (though differences at 12 months were not statistically significant). That pattern broadly fits with the longer-term trial extension data: the main potential advantage is duration, not a guaranteed bigger early effect.

Putting the private cost in context

Because Arthrosamid is commonly priced above steroid or HA injections in private practice, the value calculation is practical: a higher one-off cost may compare more favourably if the person’s profile matches the better-responder pattern (milder–moderate OA, no diabetes) and if multi-year symptom control would reduce the need for repeated shorter-acting injections. Formal cost-effectiveness data are limited, so the decision usually rests on weighing that “one injection, possibly years” upside against the uncertainty of response and the reality that advanced OA can still progress to knee replacement.

Hip hyaluronic acid or steroid injection which suits you

Choosing between a hip hyaluronic acid (HA) “gel” injection and a corticosteroid injection usually comes down to the trade-off between aiming for lubrication-style symptom control versus aiming for a fast anti-inflammatory effect. The comparison below is set out side-by-side (rather than as a list of self-posed questions) to keep the decision points clearer.

Hyaluronic acid (HA): symptom control, not cartilage repair

HA is a thickened gel intended to improve joint lubrication and shock absorption; it is not a cartilage-regeneration treatment. Systematic reviews of randomised trials in hip osteoarthritis suggest HA can reduce pain and improve function over the short to medium term (often within a few months), but average benefits appear modest and time-limited.

Randomised-trial reviews also suggest that high–molecular weight HA has not been shown to be clearly better overall than comparators such as corticosteroid, PRP, saline, or other HA preparations in pooled analyses.

Corticosteroid: faster relief, typically shorter duration

Corticosteroid is a strong anti-inflammatory medicine. In clinical practice, many people notice improvement within days, often lasting weeks to a few months; this can be particularly useful when pain is driven by an acute flare. Repeating steroid injections frequently is generally avoided, because of potential local and systemic downsides.

Shared practical points (including safety)

Both injections have small but real risks such as infection, bleeding/bruising, and a short-lived post-injection pain flare. Hip injections are often done with ultrasound guidance to improve placement accuracy in a deep joint and to help avoid nearby nerves and blood vessels.

A simple decision frame: when the priority is rapid settling of an inflammatory flare, a steroid injection is often the closer fit; when the goal is a non-steroid option that may provide steadier symptom control in earlier-stage hip OA (accepting uncertainty), HA is the usual rationale. In either case, injections tend to work best as part of a plan that still includes physiotherapy and longer-term planning if arthritis is progressing.

Can a ChondroFiller scaffold injection delay knee cartilage surgery?

For a single, localised cartilage defect in the knee (rather than widespread osteoarthritis across the whole joint), an injectable scaffold such as ChondroFiller (often referred to as “Liquid Cartilage”) is sometimes discussed as a joint-preservation option—particularly when the goal is to keep the native knee functioning and postpone more invasive cartilage surgery.

What ChondroFiller is aiming to do in the knee

ChondroFiller Liquid® is described by manufacturers and in early clinical reports as a collagen-based, defect-filling scaffold intended to support a repair response within a focal cartilage lesion, rather than a guaranteed cartilage-regeneration treatment. In some pathways it may be delivered as an injection for a well-defined defect, but much of the early clinical use in the literature has involved placement during arthroscopy rather than percutaneous injection.

What this means for “worth it?” decisions

Because published controlled evidence is limited, the decision tends to be driven by (1) how clearly the problem is a focal defect rather than diffuse osteoarthritis, (2) whether the aim is symptom improvement and function preservation versus structural “cure”, and (3) what other established options are appropriate (rehabilitation, activity modification, arthroscopic procedures, or more formal cartilage-repair techniques). A specialist assessment is needed to confirm lesion size/location, stability, and suitability, and to discuss realistic outcomes and uncertainties.

Could Lipogems fat injections delay knee replacement for you?

Rather than running through another set of self-posed questions, the key decision point with Lipogems (microfragmented adipose tissue, MFAT) is a single “bottom line”: it is a lower-burden, same-day biologic injection approach that may buy symptom relief for months, but it has not been shown to match the durability or predictability of a well-functioning total knee replacement.

What Lipogems involves on the day

In a typical outpatient appointment, a small volume of fat is taken under local anaesthetic (commonly from the abdomen or upper thigh) using a fine cannula, processed into microfragmented adipose tissue in a closed preparation system, and then injected into the arthritic knee with image guidance in the same visit. Most people go home the same day with small dressings at the harvest site and advice to ease back into activity over the following days, rather than needing a ward stay.

What the evidence suggests (and what it does not)

In comparative studies, the picture is broadly “similar outcomes”. A 53-patient randomised trial found both MFAT and hyaluronic acid improved symptoms and MRI-based measures over 6 months, with some MFAT advantages on selected scores but modest between-group differences overall.

Systematic reviews and meta-analyses comparing MFAT with PRP and other injectables/orthobiologics generally report no consistent superiority for MFAT in pain or function outcomes through 3–12 months.

How this stacks up against committing to knee replacement

Knee replacement remains a major operation with a substantial rehabilitation period and important risks (for example infection or blood clots). MFAT does not carry the same surgical recovery burden, but it has not been shown in randomised trials to reliably halt osteoarthritis progression or to be a predictable substitute for arthroplasty.

• Practical takeaway in current evidence terms: MFAT/Lipogems is best thought of as a time-buying option (often months, sometimes longer), not a guaranteed alternative to arthroplasty.

How far can steroid injections help hip bursitis pain?

Pain on the outside of the hip that gets labelled “hip bursitis” is often better described as greater trochanteric pain syndrome (GTPS)—a mix of bursal irritation and gluteal tendon overload around the greater trochanter. In clinic pathways, injections (including corticosteroid) are typically targeted to the painful peritrochanteric tissues, and are often performed with ultrasound guidance to improve placement accuracy.

Evidence syntheses of conservative GTPS treatments suggest that exercise-based rehabilitation tends to produce the largest improvements in pain and function overall, while injection-based approaches can also improve outcomes (particularly functional scores), though comparative certainty varies across studies and outcomes.

To close the loop on “deciding if private injections are right”, GTPS injections tend to sit in a plan rather than as a stand-alone fix. Consultations often focus on a simple set of decision checks:

• Is the main problem tendon-driven GTPS rather than hip joint arthritis?
• Is the goal a time-limited pain window to restart progressive loading?
• What will be measured at 4–6 weeks and at 3–12 months to judge success?

1. [1] Polyacrylamide hydrogel injections in knee osteoarthritis: A PROMs-based 24 month cohort study. (2025). https://doi.org/10.1016/j.jcot.2025.103136 https://doi.org/10.1016/j.jcot.2025.103136